Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/32664
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSakara Hutspardolen_US
dc.contributor.authorNongnuch Sirachainanen_US
dc.contributor.authorUsanarat Anurathapanen_US
dc.contributor.authorSamart Pakakasamaen_US
dc.contributor.authorDuantida Songdejen_US
dc.contributor.authorAmpaiwan Chuansumriten_US
dc.contributor.authorSomtawin Sirireungen_US
dc.contributor.authorWanpen Panthangkoolen_US
dc.contributor.authorSuradej Hongengen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T05:38:13Z-
dc.date.available2018-10-19T05:38:13Z-
dc.date.issued2013-01-01en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.96, No.SUPPL.1 (2013)en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-84876862072en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84876862072&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/32664-
dc.description.abstractObjective: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment for severe aplastic anemia (SAA). This is a single institutional review to study the feasibility of using allo-SCT for Thai children with SAA. Material and Method: Nine children with SAA (7 matched-sibling donor-SCT, 1 matched-unrelated donor-SCT and 1 haploidentical- SCT) underwent allo-SCT between October 2002 and September 2010. Cyclophosphamide and anti-thymocyte globulin (CY/ATG) were used as conditioning regimen for 4 patients with matched-sibling donor-SCT. CY/ATG and fludarabine were used for 3 patients with matched-sibling donor-SCT and one patient with haplo-identical SCT. One matched-unrelated donor-SCT received CY/ATG and total body irradiation. Results: Eight of 9 patients (89%) achieved neutrophil engraftment within 13.5 days (range 6.0-22.0). One matched-sibling donor-SCT recipient who failed to achieve engraftment died from acute renal failure and gram-negative sepsis on day 21 post allo-SCT. One matched-sibling donor-SCT case developed late graft failure on day 72 and died from invasive fungal infection. For graft versus host disease (GVHD), a haplo-identical-SCT patient died from steroid refractory grade IV acute GVHD. At last follow-up, six patients (67%) alive at a median follow-up time of 76.4 months (range 2.3-88.8). Overall survival (OS) and event-free survival (EFS) at 5 year was 63% and 65%, respectively. Conclusion: Allo-SCT is a feasible curative treatment for children with SAA in Thailand. Graft failure and severe GVHD in alternative donors SCT are responsible for major causes of death. OS and EFS probabilities are stable after the first year post transplant.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84876862072&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleAllogeneic hematopoietic stem cell transplantation for children with severe aplastic anemiaen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.